About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Adverse Outcomes Continue In Novel Program For Malaria In Pregnancy

by Julia Samuel on September 13, 2016 at 11:45 PM
Font : A-A+

Adverse Outcomes Continue In Novel Program For Malaria In Pregnancy

In sub-Saharan Africa a novel strategy to screen pregnant women for malaria with rapid diagnostic tests does not seem to lower the risk of adverse pregnancy outcomes.

In an open label randomized trial published in PLOS Medicine by Feiko ter Kuile, of the Liverpool School of Tropical Medicine, antimalarials were compared with treating all pregnant women with the malaria preventive sulfadoxine-pyrimethamine (SP).

Advertisement


During pregnancy, undetected infection with malaria parasites can lead to maternal anemia, low birthweight, and fetal loss. In areas where malaria is endemic, the World Health Organization recommends treating pregnant women with SP, but in some areas, more than 90 percent of Plasmodium parasites are resistant to SP.

In the new study, the researchers compared this standard of care to a screening approach where pregnant women are tested approximately monthly for malaria using rapid diagnostic tests and treated with a different drug, dihydroartemisinin-piperaquine (DP) only if they test positive for the parasite.
Advertisement

The study, which randomly assigned 1873 HIV-negative pregnant women at three sites in Malawi to receive either strategy, found that the risks of adverse birth outcomes, at 29.9 and 28.8 percent, was similar in the two groups.

However, the prevalence of malaria at delivery was higher in the rapid screening and DP group, at 48.7 percent, compared to 40.8 percent in the SP group (relative risk=1.19 [95% confidence interval 1.07-1.33], p=0.007), meaning an additional 8 out of every 100 pregnancies would be affected by malaria using this approach compared to broad prevention using SP.

Moreover, the rate of fetal loss was 2.6 percent, double the rate of 1.3 percent seen among women who took intermittent doses of SP (relative risk=2.06 [1.01-4.21], p=0.046). The current results, however, may not hold true in all areas because risk of malaria transmission varies according to location, as does parasite resistance to drugs.

In addition, the study design did not investigate the outcomes of using monthly DP for prevention without coupling it to screening.

"These results suggest that [intermittent screening and treatment with DP] may not be a suitable alternative strategy to replace [intermittent preventive therapy with SP] in settings similar to ours and may even predispose to unfavorable pregnancy outcomes in these settings," the authors say.

Source: Eurekalert
Advertisement
Advertisement
Advertisement

Recommended Reading

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Adverse Outcomes Continue In Novel Program For Malaria In Pregnancy Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests